AXS-14
Fibromyalgia
Phase 3Active
Key Facts
About Axsome Therapeutics
Founded in 2012 by Dr. Herriot Tabuteau, Axsome Therapeutics has evolved from a development-stage company to a commercial leader in CNS therapeutics. The company's differentiated approach focuses on novel mechanisms of action for conditions with limited treatment options, resulting in three FDA-approved products and a robust pipeline. With a strong intellectual property portfolio extending through 2040 and multiple Phase 3 programs underway, Axsome is well-positioned to expand its leadership in the CNS therapeutic space.
View full company profileTherapeutic Areas
Other Fibromyalgia Drugs
| Drug | Company | Phase |
|---|---|---|
| SP-104 (low-dose naltrexone) | Scilex Holding | Phase 2 |